|
業務類別
|
Biotechnology |
|
業務概覽
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
| 公司地址
| 701 Veterans Circle, Warminster, PA, USA, 18974 |
| 電話號碼
| +1 267 469-0914 |
| 傳真號碼
| +1 267 282-0411 |
| 公司網頁
| http://www.arbutusbio.com |
| 員工數量
| 19 |
| Mr. Tuan Nguyen |
Chief Financial Officer and Principal Accounting Officer |
美元 359.85K |
14/04/2026 |
| Ms. Lindsay Androski, C.F.A.,J.D.,M.B.A. |
Chairman of the Board, President and Chief Executive Officer |
美元 437.75K |
14/04/2026 |
|
|
| Mr. Joseph Bishop |
Independent Director |
14/04/2026 |
| Mr. Matthew Gline |
Independent Director |
14/04/2026 |
| Dr. Roger Sawhney |
Independent Director |
14/04/2026 |
| Mr. Robert Alan Beardsley, PhD |
Independent Director |
14/04/2026 |
| Ms. Lindsay Androski, C.F.A.,J.D.,M.B.A. |
Chairman of the Board, President and Chief Executive Officer |
14/04/2026 |
|
|
|
|
